Treatment of chronic myelogenous leukemia with interferons: hematologic, cellular, and genetic investigations.
Opalka
B
B
Institute for Molecular Biology, University of Essen GHS, FRG.
Kloke
O
O
Wandl
U
U
Becher
R
R
Niederle
N
N
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015139:Blotting, Southern; D002478:Cells, Cultured; D004273:DNA, Neoplasm / Q000302:isolation & purification; D006412:Hematopoietic Stem Cells / Q000032:analysis; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D011994:Recombinant Proteins; D012074:Remission Induction
D004273:DNA, Neoplasm; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D007371:Interferon-gamma